Hangzhou DNano MetaBio Technology Co., LTD. (DNano MetaBio) was established in 2022. Focusing on the designing of nucleic acid nanocarriers, it is the first team in the world to apply this technology to drug delivery and in vivo biological tests.
Guided by the construction of innovative drugs to meet clinical needs, together with the mission of "Innovating biotechnology, protecting life and health", DNano MetaBio develops nucleic acid nanocarriers to achieve accurate, efficient, and safe drug delivery inside the human body, which includes but not limited to chemotherapy drugs, protein drugs, nucleic acid drugs and so on.
DNano MetaBio uses its unique structure design and sequence optimizing platform of nucleic acid nanocarriers to accurately and quantitatively load a variety of functional components, which solves the pain points of the nano-drug delivery field, such as uneven carrier sizes and inability to accurately control drug loading capacity.
The precisely designed nucleic acid nanocarriers have multiple functions such as organ selective active targeting and intelligent controlled release of drugs, which can effectively improve the safety and stability of drug carriers, reduce the immunogenicity of the carriers and drugs, and greatly meet the clinical demand for innovative drugs.
At the same time, DNano MetaBio is committed to promoting the transformation of nucleic acid nanocarriers from the laboratory stage to the clinical use stage. So far, it has laid out a number of innovative drug research and development pipelines based on nucleic acid nanocarrier technology, focusing on the clinical treatment needs of malignant tumors, metabolic diseases, rare diseases, and other diseases.